Cytokinetics, Inc.  

(Public, NASDAQ:CYTK)   Watch this stock  
Find more results for CYTK
3.50
+0.05 (1.45%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.37 - 3.50
52 week 3.05 - 13.26
Open 3.46
Vol / Avg. 119,663.00/293,207.00
Mkt cap 128.13M
P/E     -
Div/yield     -
EPS -0.70
Shares 36.61M
Beta 1.32
Inst. own 66%
Oct 30, 2014
Q3 2014 Cytokinetics Inc Earnings Call - 4:30PM EDT - Add to calendar
Oct 30, 2014
Q3 2014 Cytokinetics Inc Earnings Release - 4:00PM EDT - Add to calendar
Aug 14, 2014
Cytokinetics Inc at Canaccord Genuity Growth Conference
Jul 30, 2014
Q2 2014 Cytokinetics Inc Earnings Call - Webcast
Jul 30, 2014
Q2 2014 Cytokinetics, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -107.52% -110.01%
Operating margin -107.95% -110.59%
EBITD margin - -109.18%
Return on average assets -33.02% -41.95%
Return on average equity -40.74% -54.15%
Employees 85 -
CDP Score - -

Address

280 East Grand Avenue
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-6243000 (Phone)
+1-650-6243010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company�s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac sarcomere, the basic unit of muscle contraction in the heart. Its lead drug candidate CK-2017357 is subject of a Phase IIa clinical trials program. CK-2017357 is useful in treating diseases or medical conditions associated with skeletal muscle weakness or wasting. In March 2010, CK-2017357 received an orphan drug designation from the FDA for the treatment of amyotrophic lateral sclerosis.

Officers and directors

L.Patrick Patrick Gage Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Robert I. Blum President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Sharon A. Barbari Chief Financial Officer, Executive Vice President - Finance
Age: 59
Bio & Compensation  - Reuters
David W. Cragg Senior Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Bonnie A. Charpentier Ph.D. Senior Vice President - Regulatory Affairs and Compliance
Age: 60
Bio & Compensation  - Reuters
Fady I. Malik M.D., Ph.D. Senior Vice President - Research and Early Development
Age: 49
Bio & Compensation  - Reuters
Andrew A. Wolff M.D. Senior Vice President - Clinical Research and Development, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Santo J. Costa Independent Director
Age: 68
Bio & Compensation  - Reuters
Denise M. Gilbert Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
John T. Henderson M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters